High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes.

Zhang, Yi; Thamer, Mae; Kaufman, James S; Cotter, Dennis J; Hernán, Miguel A

Zhang, Yi; Thamer, Mae; Kaufman, James S; Cotter, Dennis J; Hernán, Miguel A.

Affiliation

Zhang Y; Medical Technology and Practice Patterns Institute, 4733 Bethesda Avenue, Bethesda, MD 20814, USA.

Kidney Int ; 80(6): 663-9, 2011 Sep.

Article in En | MEDLINE | ID: mdl-21697811

Subject(s)

Diabetic Nephropathies/therapy; Erythropoietin/administration & dosage; Hematinics/administration & dosage; Renal Dialysis/methods; Aged; Cardiovascular Diseases/etiology; Databases, Factual; Diabetic Cardiomyopathies/etiology; Diabetic Nephropathies/mortality; Erythropoietin/adverse effects; Female; Hematinics/adverse effects; Humans; Male; Medicare; Recombinant Proteins/administration & dosage; Recombinant Proteins/adverse effects; Renal Dialysis/adverse effects; Renal Dialysis/mortality; Risk Factors; United States

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Erythropoietin / Renal Dialysis / Diabetic Nephropathies / Hematinics Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: Kidney Int Year: 2011 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google